EA200601982A1 - AMINOPYRIDINE DERIVATIVES AS SELECTIVE D3 AGRONISTS - DOPAMINE RECEPTORS - Google Patents

AMINOPYRIDINE DERIVATIVES AS SELECTIVE D3 AGRONISTS - DOPAMINE RECEPTORS

Info

Publication number
EA200601982A1
EA200601982A1 EA200601982A EA200601982A EA200601982A1 EA 200601982 A1 EA200601982 A1 EA 200601982A1 EA 200601982 A EA200601982 A EA 200601982A EA 200601982 A EA200601982 A EA 200601982A EA 200601982 A1 EA200601982 A1 EA 200601982A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorder
disorders
sexual dysfunction
sex
selective
Prior art date
Application number
EA200601982A
Other languages
Russian (ru)
Inventor
Шарлотта Мойра Норфор Аллертон
Эндрю Саймон Кук
Дейвид Хепуорт
Дункан Чарльз Миллер
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34970000&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200601982(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0411891A external-priority patent/GB0411891D0/en
Priority claimed from GB0412463A external-priority patent/GB0412463D0/en
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of EA200601982A1 publication Critical patent/EA200601982A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

В настоящем изобретении предложены соединения формулы (I), которые представляют собой класс агонистов дофамина, более конкретно, класс агонистов, которые являются более селективными в отношении D3 по сравнению с D2. Эти соединения являются полезными для лечения и/или предотвращения сексуальной дисфункции, например женской сексуальной дисфункции (FSD), в частности расстройства женского полового возбуждения (FSAD), гипоактивного расстройства полового влечения (HSDD; отсутствие интереса к сексу), женского оргазмического расстройства (FOD; неспособность достижения оргазма); и мужской сексуальной дисфункции, в частности мужской эректильной дисфункции (MED). Мужская сексуальная дисфункция при упоминании здесь означает, что она включает эякуляторные расстройства, такие как преждевременная эякуляция, аноргазмия (неспособность достижения оргазма) или расстройства влечения, такие как гипоактивное расстройство полового влечения (HSDD; отсутствие интереса к сексу). Эти соединения также являются полезными в лечении нейропсихиатрических расстройств и нейродегенеративных расстройств.The present invention provides compounds of formula (I), which are a class of dopamine agonists, more specifically, a class of agonists that are more selective for D3 compared to D2. These compounds are useful for the treatment and / or prevention of sexual dysfunction, for example female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD; lack of interest in sex), female orgasmic disorder (FOD; failure to achieve orgasm); and male sexual dysfunction, in particular male erectile dysfunction (MED). Male sexual dysfunction, when referred to here, means that it includes ejaculatory disorders such as premature ejaculation, anorgasmia (inability to achieve orgasm) or attraction disorders such as hypoactive sex drive disorder (HSDD; lack of interest in sex). These compounds are also useful in the treatment of neuropsychiatric disorders and neurodegenerative disorders.

EA200601982A 2004-05-27 2005-05-17 AMINOPYRIDINE DERIVATIVES AS SELECTIVE D3 AGRONISTS - DOPAMINE RECEPTORS EA200601982A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0411891A GB0411891D0 (en) 2004-05-27 2004-05-27 New aminopyridine derivatives and their use as pharmaceuticals
GB0412463A GB0412463D0 (en) 2004-06-03 2004-06-03 New aminopyridine derivatives and their use as pharmaceuticals
PCT/IB2005/001554 WO2005115985A1 (en) 2004-05-27 2005-05-17 Aminopyridine derivatives as selective dopamine d3 agonists

Publications (1)

Publication Number Publication Date
EA200601982A1 true EA200601982A1 (en) 2007-04-27

Family

ID=34970000

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601982A EA200601982A1 (en) 2004-05-27 2005-05-17 AMINOPYRIDINE DERIVATIVES AS SELECTIVE D3 AGRONISTS - DOPAMINE RECEPTORS

Country Status (21)

Country Link
EP (1) EP1758862A1 (en)
JP (1) JP4198183B2 (en)
AP (1) AP2006003824A0 (en)
AR (1) AR049548A1 (en)
AU (1) AU2005247699A1 (en)
BR (1) BRPI0511571A (en)
CA (1) CA2567935C (en)
EA (1) EA200601982A1 (en)
EC (1) ECSP067029A (en)
GT (1) GT200500125A (en)
IL (1) IL179314A0 (en)
MA (1) MA28607B1 (en)
MX (1) MXPA06013786A (en)
NL (1) NL1029139C2 (en)
NO (1) NO20065326L (en)
PA (1) PA8635101A1 (en)
PE (1) PE20060366A1 (en)
SV (1) SV2005002129A (en)
TW (1) TW200609216A (en)
UY (1) UY28925A1 (en)
WO (1) WO2005115985A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0502509D0 (en) * 2005-02-07 2005-03-16 Pfizer Ltd Novel salt form of a dopamine agonist
MX2011008583A (en) * 2009-02-13 2011-12-12 Bayer Pharma AG Fused pyrimidines.
EP2558437B1 (en) * 2010-04-12 2015-08-05 Supernus Pharmaceuticals, Inc. Methods for producing viloxazine salts and novel polymorphs thereof
EP2726171B1 (en) 2011-06-30 2017-05-17 Donaldson Company, Inc. Air/oil separator assemblies
GB2543296A (en) * 2015-10-13 2017-04-19 Indivior Uk Ltd Dopamine D3 receptor antagonists having a morpholine moiety
EA037520B1 (en) 2016-07-20 2021-04-07 Новартис Аг Aminopyridine derivatives and their use as selective alk-2 inhibitors
EP3953350A1 (en) * 2019-04-12 2022-02-16 The United States of America, as Represented by The Department of Health and Human Services D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof
EP4061367A1 (en) 2019-11-22 2022-09-28 Incyte Corporation Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
WO2021257532A1 (en) 2020-06-16 2021-12-23 Incyte Corporation Alk2 inhibitors for the treatment of anemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) * 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
SI1572214T1 (en) * 2002-12-10 2010-07-30 Pfizer Ltd Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction

Also Published As

Publication number Publication date
AU2005247699A1 (en) 2005-12-08
EP1758862A1 (en) 2007-03-07
CA2567935A1 (en) 2005-12-08
PA8635101A1 (en) 2006-05-16
GT200500125A (en) 2006-01-10
UY28925A1 (en) 2005-12-30
MXPA06013786A (en) 2007-01-25
PE20060366A1 (en) 2006-05-15
JP4198183B2 (en) 2008-12-17
IL179314A0 (en) 2007-03-08
TW200609216A (en) 2006-03-16
NL1029139C2 (en) 2006-06-19
MA28607B1 (en) 2007-05-02
CA2567935C (en) 2009-10-27
AR049548A1 (en) 2006-08-16
BRPI0511571A (en) 2008-01-02
JP2008500331A (en) 2008-01-10
NO20065326L (en) 2006-12-19
ECSP067029A (en) 2006-12-29
NL1029139A1 (en) 2005-11-30
SV2005002129A (en) 2005-12-13
AP2006003824A0 (en) 2006-12-31
WO2005115985A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
EA200601982A1 (en) AMINOPYRIDINE DERIVATIVES AS SELECTIVE D3 AGRONISTS - DOPAMINE RECEPTORS
GEP20217265B (en) Glp-1 receptor agonists and uses thereof
CY1119057T1 (en) CONNECTOR OPTIONAL RECEPTORS AND METHODS OF USE AND MANUFACTURE
MY195437A (en) Methods of Treatment for Cholestatic and Fibrotic Diseases
EA201101524A1 (en) METHOD AND COMPOSITION FOR TREATMENT OF CONDITION ASSOCIATED WITH CHEMOSENSOR RECEPTOR
MA39172A1 (en) Heterocyclic bicyclic derivatives as bromodomaine inhibitors
PH12017501522B1 (en) Antibodies to tau and uses thereof
EP2349170C0 (en) Apparatus for the treatment of female sexual dysfunction
CL2012003132A1 (en) Compounds derived from heteroaryl-cyclohexyl-tetraazabenzo [e] azulenes, vla receptor antagonists; Preparation process; pharmaceutical composition; and its use for the prevention or treatment of dysmenorrhea, male or female sexual dysfunction, hypertension and liver cirrhosis, among others.
CL2012002905A1 (en) Compounds derived from heteroaryl-cyclohexyl-tetraazabenzo (e) substituted azanes, vasopressin v1a receptor modulators; preparation procedure; pharmaceutical composition; and its use for the prevention or treatment of dysmenorrhea, male or female sexual dysfunction, anxiety, among others.
PE20142040A1 (en) DERIVATIVES OF 6,7-DIHIDRO-5H-BENZO [7] ANULENO, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PRODUCTS THAT INCLUDE THE SAME AND THEIR USE IN THE PREPARATION OF MEDICINES
UA116894C2 (en) Novel pyrazine derivatives as cb2 receptor agonists
EA201791058A1 (en) MORFOLIN- and 1,4-OXAZAZEPAN-AMIDA AS AN AGONISTS OF SOMATOSTATIN RECEPTOR Subtype 4 (SSTR4)
MX2022011972A (en) Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same.
AR076617A1 (en) COMPOUNDS OF AMINOPIRAZOL TRIAZOLOTIADIAZOL INHIBITORS OF PROTEIN QUINASE C-MET.
TW200607500A (en) New indazole and indolone derivatives and their use as pharmaceuticals
PE20160787A1 (en) NEW COMPOUND FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA
DOP2005000095A (en) NEW DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS
DOP2005000093A (en) NEW DERIVATIVES OF INDAZOL AND INDOLONA AND ITS USE AS PHARMACEUTICAL PRODUCTS
EA201391459A1 (en) TREATMENT MODES
MX2012014968A (en) Fixed doses of a tadalafil and dapoxetine pharmaceutical combination.
EA201792070A1 (en) MEANS FOR THE TREATMENT OF THE FOREQUARTEROUS DYSFUNCTION
MA44836A (en) KIDNEY POLYCYSTIC SYNDROME TREATMENT METHODS
MA38791A1 (en) Connecting piece for engine
RU2014137640A (en) METHOD FOR SEGMENTAL STRENGTHENING OF THE INSIDE SURFACE OF THE BUSH